top of page
VTS-72 aims to be the next generation oral fumarate therapy, that may hold potential as a treatment for MS with fewer side effects and other clinical benefits for these patients.
​
​
Aiming to submit NDA in 2020-2021.
VTS-72 aims to be the next generation oral fumarate therapy, that may hold potential as a treatment for MS with fewer side effects and other clinical benefits for these patients.
​
​
Aiming to submit NDA in 2020-2021.
VTS-K: Ketamine + VTS Aspirin for Postoperative Pain
VTS-K: Ketamine + VTS Aspirin for Postoperative Pain
Next-generation therapies
Vitalis is exploring innovative ways to improve existing treatments for multiple sclerosis, post-operative pain (non-opioid), and dyslipidemia.
bottom of page